Cytology and histopathology have poor to fair agreement for determination of neoplastic or nonneoplastic lesions in dogs with splenic masses or nodules.
To evaluate the correlation between cytology and histopathology of splenic masses or nodular lesions in dogs.
Retrospective medical record review from January 2014 to July 2022 of dogs that had a splenic mass or nodular lesion and cytologic and histopathologic evaluation within 90 days of each other. Slide review was conducted by a single pathologist from each subspecialty and recorded as neoplastic, possibly neoplastic, or nonneoplastic.
33 dogs were included and had a median of 4 days (range, 0 to 90 days) between cytologic and histopathologic evaluation. Cytologic and histopathologic results agreed in 18 of 33 dogs (55%; 12 nonneoplastic and 6 neoplastic), although the type of neoplasm differed in one of these (sarcoma vs lymphoma). There was disagreement in 8 of 33 dogs (24%; 7 neoplastic on histopathology and nonneoplastic on cytology, 1 nonneoplastic on histopathology and neoplastic on cytology). When including a possibly neoplastic cytologic diagnosis as neoplastic, there was agreement in 22 of 33 dogs (67%) and disagreement in 11 of 33 dogs (33%). In dogs with a neoplastic or possibly neoplastic cytologic diagnosis, 10 of 14 (71%) were neoplastic on histopathology. In dogs with a nonneoplastic cytologic diagnosis, 12 of 19 (63%) were nonneoplastic on histopathology.
Cytologic diagnosis correlated with histopathologic diagnosis of splenic masses or nodular lesions in 55% to 67% of dogs. Cytology was accurate in 71% of neoplastic and 63% of nonneoplastic splenic masses or nodular lesions.
There is poor to fair agreement between cytology and histopathology in dogs with splenic masses or nodular lesions. A neoplastic cytologic diagnosis more commonly agrees with histopathology than a nonneoplastic diagnosis.
Retrospective medical record review from January 2014 to July 2022 of dogs that had a splenic mass or nodular lesion and cytologic and histopathologic evaluation within 90 days of each other. Slide review was conducted by a single pathologist from each subspecialty and recorded as neoplastic, possibly neoplastic, or nonneoplastic.
33 dogs were included and had a median of 4 days (range, 0 to 90 days) between cytologic and histopathologic evaluation. Cytologic and histopathologic results agreed in 18 of 33 dogs (55%; 12 nonneoplastic and 6 neoplastic), although the type of neoplasm differed in one of these (sarcoma vs lymphoma). There was disagreement in 8 of 33 dogs (24%; 7 neoplastic on histopathology and nonneoplastic on cytology, 1 nonneoplastic on histopathology and neoplastic on cytology). When including a possibly neoplastic cytologic diagnosis as neoplastic, there was agreement in 22 of 33 dogs (67%) and disagreement in 11 of 33 dogs (33%). In dogs with a neoplastic or possibly neoplastic cytologic diagnosis, 10 of 14 (71%) were neoplastic on histopathology. In dogs with a nonneoplastic cytologic diagnosis, 12 of 19 (63%) were nonneoplastic on histopathology.
Cytologic diagnosis correlated with histopathologic diagnosis of splenic masses or nodular lesions in 55% to 67% of dogs. Cytology was accurate in 71% of neoplastic and 63% of nonneoplastic splenic masses or nodular lesions.
There is poor to fair agreement between cytology and histopathology in dogs with splenic masses or nodular lesions. A neoplastic cytologic diagnosis more commonly agrees with histopathology than a nonneoplastic diagnosis.